New drug duo aims to stall pancreatic cancer after chemo

NCT ID NCT04477343

Ongoing Disease control Sponsor: University of Rochester Source: ClinicalTrials.gov ↗

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This trial tests whether combining two drugs—SX-682 and nivolumab—can safely help people with metastatic pancreatic cancer that has not worsened after at least 16 weeks of first-line chemotherapy. The main goal is to find the highest tolerable dose of SX-682 when given with nivolumab. Researchers will also track how long participants live without the cancer growing and overall survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SX-682 and nivolumab
What this could lead to: If successful, this combination could offer a new maintenance option to help keep metastatic pancreatic cancer from progressing after initial chemotherapy.
What could go wrong: This is an early, small Phase 1 trial focused on safety and dosing, not yet on effectiveness. The combination may cause side effects or fail to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic ductal adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC CANCER PANCREATIC DUCTAL ADENOCARCINOMA

Contacts and locations

Show contact details

Locations

University of Rochester

Rochester, New York, 14642, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.